Dermatomyositis News and Research

Latest Dermatomyositis News and Research

Statin medications can cause necrotizing myopathy in some patients

Statin medications, such as Crestor, Lipitor, and other lipid-lowering medications, have been prescribed increasingly in recent years to reduce cardiovascular disease and mortality in high risk individuals.

6 Jun 2017

Researchers develop ultrasensitive method to detect protein involved in autoimmune diseases

Researchers in France have developed a new method that will allow doctors to detect minute amounts of a protein called interferon-a in patient samples.

18 Apr 2017

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses.

6 Jul 2016

Anti-TNF therapy offers new hope to JDM patients

The results of a UK study presented today at the European League Against Rheumatism Annual Congress showed that tumour necrosis factor inhibitor (anti-TNF) treatment is effective at improving both muscle and skin involvement in children with juvenile dermatomyositis (JDM).

13 Jun 2016

African-American patients with connective tissue diseases at risk for cardiovascular disease

A study based on medical records from more than a quarter million adult patients found that African-American patients with connective tissue diseases such as lupus or rheumatoid arthritis were twice as likely as white patients to suffer from narrowed or atherosclerotic blood vessels, which increase the risk of a heart attack, stroke or death.

5 Feb 2016

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Former all-American wrestler speaks about his personal battle with chronic muscle disease

In 2009, Mike Powell was where he'd always wanted to be. A former all-American wrestler himself, he'd returned to his Chicago-area high school to become the toughest wrestling coach around, inspiring young athletes with a brutal mix of love and punishing workouts.

2 Sep 2015

Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Mohamed Boutjdir, PhD, professor of medicine, cell biology, and physiology and pharmacology at SUNY Downstate Medical Center, has led a study with international collaborators identifying the mechanism by which patients with various autoimmune and connective tissue disorders may be at risk for life-threatening cardiac events if they take certain anti-histamine or anti-depressant medications.

7 Jul 2015

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014

Baylor receives $3.3M grant from NIAMS to advance research in autoimmune diseases

Baylor Research Institute has received a $3.3 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), one of the National Institutes of Health, to fund its Autoimmunity Center of Excellence.

14 May 2014

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Idera Pharmaceuticals, Inc. today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.

28 Mar 2014

Researchers create specific tests to detect cancer biomarkers in patients with dermatomyositis

Researchers from major universities in the U.S. have developed specific tests to identify cancer biomarkers in patients with dermatomyositis-a systemic inflammatory disease associated with increased risk of malignancy.

3 Sep 2013

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis Pharma AG and Novartis AG.

11 Jun 2013

Age at onset influences juvenile dermatomyositis course

Children diagnosed with juvenile dermatomyositis at age 3 years or earlier have milder symptoms than patients with later onset, research suggests.

24 Sep 2012

Questcor second quarter net sales increase to $112.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2012.

24 Jul 2012

Intravenous immune globulin effective treatment for GBS, CIDP

Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating polyneuropathy (CIDP), according to a guideline issued by the American Academy of Neurology.

27 Mar 2012

Questcor fourth quarter net sales increase to $75.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2011.

22 Feb 2012

Most autoimmune diseases associated with increased risk of blood clots on the lung

Autoimmune diseases, in which the immune system attacks the body, are fairly common. Thyroid diseases, type 1 diabetes, rheumatoid arthritis, psoriasis and inflammatory bowel disease are some examples. Autoimmune diseases are associated with increased inflammation in the tissue, which in some cases is linked to an increased propensity to develop clots in the veins.

29 Nov 2011

Positive results from etanercept pilot study against dermatomyositis

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy.

17 Jun 2011

Dermatomyositis News and Research

Latest Dermatomyositis News and Research

Statin medications can cause necrotizing myopathy in some patients

Researchers develop ultrasensitive method to detect protein involved in autoimmune diseases

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Anti-TNF therapy offers new hope to JDM patients

African-American patients with connective tissue diseases at risk for cardiovascular disease

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Former all-American wrestler speaks about his personal battle with chronic muscle disease

Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Idera collaborates with TMA to advance new potential treatment approach for myositis

Baylor receives $3.3M grant from NIAMS to advance research in autoimmune diseases

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Researchers create specific tests to detect cancer biomarkers in patients with dermatomyositis

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Age at onset influences juvenile dermatomyositis course

Questcor second quarter net sales increase to $112.5 million

Intravenous immune globulin effective treatment for GBS, CIDP

Questcor fourth quarter net sales increase to $75.5 million

Most autoimmune diseases associated with increased risk of blood clots on the lung

Positive results from etanercept pilot study against dermatomyositis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Dermatomyositis News and Research

Latest Dermatomyositis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in